Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application
Miivo Launches Low Cost, Fully Automated AI Customer Insights Tool for Small to Medium Size Businesses
Goldgroup Accelerates Growth Strategy Following Transformational Merger; Company Advances Multi-Asset Drill Programs, Mine Development and Expansion Plans
